Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform
Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...
Celregen Therapeutics
Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion
Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...